Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas

Oncogene

Volumn 27, Issue 19, 2008, Pages 2728-2736

  Colomba, A ^a,b   Courilleau, D ^a,b   Ramel, D ^a,b   Billadeau, D D ^c   Espinos, E ^a,b   Delsol, G ^a,b   Payrastre, B ^a,b   Gaits Iacovoni, F ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c MAYO CLINIC   (United States)

^d CHU PURPAN   (France)

Author keywords

Anaplastic large cell lymphomas; NPM ALK; Rho GTPases; Vav3

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; GUANOSINE TRIPHOSPHATASE; HYBRID PROTEIN; NUCLEOPHOSMIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE LYN; PROTEIN KINASE P60; PROTEIN SH2; PROTEIN TYROSINE KINASE; PROTEIN VAV3; RAC1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL LINE, TUMOR; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MICE; NIH 3T3 CELLS; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-VAV; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 42549168106     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210921     Document Type: Article

References (47)

1. Ambrogio C, Voena C, Manazza AD, Piva R, Riera L, Barberis L et al. (2005). p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood 106: 3907-3916.
2. Amin HM, Medeiros LJ, Ma Y, Feretzaki M, Das P, Leventaki V et al. (2003). Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 22: 5399-5407.
3. Armstrong F, Duplantier MM, Trempat P, Hieblot C, Lamant L, Espinos E et al. (2004). Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 23: 6071-6082.
4. Aznar S, Fernandez-Valeron P, Espina C, Lacal JC. (2004). Rho GTPases: potential candidates for anticancer therapy. Cancer Lett 206: 181-191.
5. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. (1998). Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 18: 6951-6961.
6. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. (2000). Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptoticsignaling pathway. Blood 96: 4319-4327.
7. Bassermann F, Jahn T, Miething C, Seipel P, Bai RY, Coutinho S et al. (2002). Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway. J Biol Chem 277: 12437-12445.
8. Benard V, Bokoch GM. (2002). Assay of Cdc42, Rac, and Rho GTPase activation by affinity methods. Methods Enzymol 345: 349-359.
9. Bustelo XR. (2000). Regulatory and signaling properties of the Vav family. Mol Cell Biol 20: 1461-1477.
10. Bustelo XR. (2001). Vav proteins, adaptors and cell signaling. Oncogene 20: 6372-6381.
11. Charvet C, Canonigo AJ, Billadeau DD, Altman A. (2005). Membrane localization and function of Vav3 in T cells depend on its association with the adapter SLP-76. J Biol Chem 280: 15289-15299.
12. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J et al. (2003). NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101: 1919-1927.
13. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R et al. (2005). Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11: 623-629.
14. Cho YJ, Zhang B, Kaartinen V, Haataja L, de Curtis I, Groffen J et al. (2005). Generation of rac3 null mutant mice: role of Rac3 in Bcr/ Abl-caused lymphoblastic leukemia. Mol Cell Biol 25: 5777-5785.
15. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L et al. (2005). Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 115: 369-378.
16. Crockett DK, Lin Z, Elenitoba-Johnson KS, Lim MS. (2004). Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 23: 2617-2629.
17. Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW et al. (2004). Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 103: 1464-1471.
18. Cussac D, Pichereaux C, Colomba A, Capilla F, Pont F, Gaits-Iacovoni F et al. (2006). Proteomic analysis of anaplastic lymphoma cell lines: identification of potential tumour markers. Proteomics 6: 3210-3222.
19. Duyster J, Bai RY, Morris SW. (2001). Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20: 5623-5637.
20. Falini B. (2001). Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol 114: 741-760.
21. Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G et al. (1998). ALK expression defines a distinct group of T/null lymphomas ('ALK lymphomas') with a wide morphological spectrum. Am J Pathol 153: 875-886.
22. Fawal M, Armstrong F, Ollier S, Dupont H, Touriol C, Monsarrat B et al. (2006). A 'liaison dangereuse' between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK. Blood 108: 2780-2788.
23. Fritz G, Kaina B. (2006). Rho GTPases: promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets 6: 1-14.
24. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S et al. (1996). Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA 93: 4181-4186.
25. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. (2004). Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA 101: 7618-7623.
26. Genth H, Huelsenbeck J, Hartmann B, Hofmann F, Just I, Gerhard R. (2006). Cellular stability of Rho-GTPases glucosylated by Clostridium difficile toxin B. FEBS Lett 580: 3565-3569.
27. Hall A. (1998). Rho GTPases and the actin cytoskeleton. Science 279: 509-514.
28. Hall A. (2005). Rho GTPases and the control of cell behaviour. Biochem Soc Trans 33: 891-895.
29. Honorat JF, Ragab A, Lamant L, Delsol G, Ragab-Thomas J. (2006). SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood 107: 4130-4138.
30. Hornstein I, Alcover A, Katzav S. (2004). Vav proteins, masters of the world of cytoskeleton organization. Cell Signal 16: 1-11.
31. Lamant L, De Reynies A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S et al. (2006). Gene expression profiling of systemic anaplastic large cell lymphoma reveals differences depending on ALK status and two distinct morphological ALK+ subtypes. Blood 109: 2156-2164.
32. Lamant L, Espinos E, Duplantier M, Dastugue N, Robert A, Allouche M et al. (2004). Establishment of a novel anaplastic large-cell lymphoma-cell line (COST) from a 'small-cell variant' of ALCL. Leukemia 18: 1693-1698.
33. Lamant L, Meggetto F, al Saati T, Brugieres L, de Paillerets BB, Dastugue N et al. (1996). High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 87: 284-291.
34. Lim MS, Elenitoba-Johnson KS. (2006). Mass spectrometry-based proteomic studies of human anaplastic large cell lymphoma. Mol Cell Proteomics 5: 1787-1798.
35. Liu BP, Burridge K. (2000). Vav2 activates Rac1, Cdc42, and RhoA downstream from growth factor receptors but not beta1 integrins. Mol Cell Biol 20: 7160-7169.
36. Llorca O, Arias-Palomo E, Zugaza JL, Bustelo XR. (2005). Global conformational rearrangements during the activation of the GDP/ GTP exchange factor Vav3. EMBO J 24: 1330-1340.
37. Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA. (2007). Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene 26: 813-821.
38. Marzec M, Kasprzycka M, Ptasznik A, Wlodarski P, Zhang Q, Odum N et al. (2005). Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest 85: 1544-1554.
39. Movilla N, Bustelo XR. (1999). Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol Cell Biol 19: 7870-7885.
40. Petit P, Breard J, Montalescot V, El Hadj NB, Levade T, Popoff M et al. (2003). Lethal toxin from Clostridium sordellii induces apoptotic cell death by disruption of mitochondrial homeostasis in HL-60 cells. Cell Microbiol 5: 761-771.
41. Rottner K, Hall A, Small JV. (1999). Interplay between Rac and Rho in the control of substrate contact dynamics. Curr Biol 9: 640-648.
42. Sahai E, Marshall CJ. (2002). RHO-GTPases and cancer. Nat Rev Cancer 2: 133-142.
43. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson Jr HF. (2004). Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 10: 3800-3806.
44. Thompson MA, Stumph J, Henrickson SE, Rosenwald A, Wang Q, Olson S et al. (2005). Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol 36: 494-504.
45. Titus B, Schwartz MA, Theodorescu D. (2005). Rho proteins in cell migration and metastasis. Crit Rev Eukaryot Gene Expr 15: 103-114.
46. Zakaria S, Gomez TS, Savoy DN, McAdam S, Turner M, Abraham RT et al. (2004). Differential regulation of TCR-mediated gene transcription by Vav family members. J Exp Med 199: 429-434.
47. Zeng L, Sachdev P, Yan L, Chan JL, Trenkle T, McClelland M et al. (2000). Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol 20: 9212-9224.